500-P200-100UG

antibody from Invitrogen Antibodies

Targeting: CXCL16 CXCLG16, SR-PSOX, SRPSOX

Provider product page for 500-P200-100UG

Western blot

ELISA

Antibody data

Antibody Data
Antigen structure
References [7]
Comments [0]
Validations
ELISA [1]

Submit

Product number: 500-P200-100UG - Provider product page
Provider: Invitrogen Antibodies
Product name: CXCL16 Polyclonal Antibody, PeproTech®
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: AA Sequence of recombinant protein: NEGSVTGSCY CGKRISSDSP PSVQFMNRLR KHLRAYHRCL YYTRFQLLSW SVCGGNKDPW VQELMSCLDL KECGHAYSGI VAHQKHLLP. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human CXCL16. Anti-Human CXCL16-specific antibody was purified by affinity chromatography employing an immobilized Human CXCL16 matrix. Sandwich ELISA: To detect Human CXCL16 by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human CXCL16 (500-P200Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human CXCL16. Western Blot: To detect Human CXCL16 by Western Blot analysis this antibody can be used at a concentration of 0.1- 0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human CXCL16 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Reactivity: Human
Host: Rabbit
Vial size: 100 µg
Concentration: 0.1-1.0 mg/mL
Storage: -20°C

CXCL16 protein structure - 500-P200-100UG shown in red.

Submitted references Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR
Cell 2020 May 28;181(5):1036-1045.e9

The Global Phosphorylation Landscape of SARS-CoV-2 Infection.

Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, Polacco BJ, Melnyk JE, Ulferts S, Kaake RM, Batra J, Richards AL, Stevenson E, Gordon DE, Rojc A, Obernier K, Fabius JM, Soucheray M, Miorin L, Moreno E, Koh C, Tran QD, Hardy A, Robinot R, Vallet T, Nilsson-Payant BE, Hernandez-Armenta C, Dunham A, Weigang S, Knerr J, Modak M, Quintero D, Zhou Y, Dugourd A, Valdeolivas A, Patil T, Li Q, Hüttenhain R, Cakir M, Muralidharan M, Kim M, Jang G, Tutuncuoglu B, Hiatt J, Guo JZ, Xu J, Bouhaddou S, Mathy CJP, Gaulton A, Manners EJ, Félix E, Shi Y, Goff M, Lim JK, McBride T, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, De Wit E, Leach AR, Kortemme T, Shoichet B, Ott M, Saez-Rodriguez J, tenOever BR, Mullins RD, Fischer ER, Kochs G, Grosse R, García-Sastre A, Vignuzzi M, Johnson JR, Shokat KM, Swaney DL, Beltrao P, Krogan NJ
Cell 2020 Aug 6;182(3):685-712.e19

The Chemokine Receptor CXCR6 Evokes Reverse Signaling via the Transmembrane Chemokine CXCL16.

Adamski V, Mentlein R, Lucius R, Synowitz M, Held-Feindt J, Hattermann K
International journal of molecular sciences 2017 Jul 8;18(7)

Transmembrane chemokines act as receptors in a novel mechanism termed inverse signaling.

Hattermann K, Gebhardt H, Krossa S, Ludwig A, Lucius R, Held-Feindt J, Mentlein R
eLife 2016 Jan 21;5:e10820

Human P2X7 receptor activation induces the rapid shedding of CXCL16.

Pupovac A, Foster CM, Sluyter R
Biochemical and biophysical research communications 2013 Mar 22;432(4):626-31

Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.

Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ, Phillips K, Kahaleh B, Seibold JR, Koch AE
Arthritis research & therapy 2011 Feb 8;13(1):R18

Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin.

Scholz F, Schulte A, Adamski F, Hundhausen C, Mittag J, Schwarz A, Kruse ML, Proksch E, Ludwig A
The Journal of investigative dermatology 2007 Jun;127(6):1444-55